Combining Alendronate and Osteoprotegerin Improves Bone Strength in Rats
Author Information
Author(s): Wang Yan, Huang Peng, Tang Pei-Fu, Chan Kai-Ming, Li Gang
Primary Institution: The General Hospital of People's Liberation Army, Beijing, PR China
Hypothesis
Does the combination of Alendronate and Osteoprotegerin enhance bone mass and mechanical properties more than either treatment alone in ovariectomized rats?
Conclusion
The combined use of Osteoprotegerin and Alendronate may be a new treatment strategy for reversing bone loss and restoring bone quality in osteoporotic disorders.
Supporting Evidence
- The ALN+OPG-Fc treatment group had significantly increased mechanical strength compared to the ALN and OPG-Fc groups.
- RANKL protein expression was significantly decreased in the ALN and ALN+OPG-Fc treatment groups.
- All treatment groups prevented bone loss in ovariectomized rats.
Takeaway
Using two medicines together can make bones stronger than using just one medicine by itself.
Methodology
Ovariectomized rats were treated with Alendronate, Osteoprotegerin, or both, and various bone properties were measured.
Limitations
The study duration was relatively short and only one regime of rhOPG-Fc administration was tested.
Participant Demographics
12 weeks old female Sprague-Dawley rats, body weight 350-400 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website